BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2014 10:03:00 AM | Browse: 441 | Download: 432
Publication Name World Journal of Diabetes
Manuscript ID 9134
Country/Territory India
2014-01-23 15:59
Peer-Review Started
2014-01-23 22:10
To Make the First Decision
2014-02-27 09:38
Return for Revision
2014-03-11 21:13
Second Decision
2014-04-19 14:28
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-04-19 14:40
Articles in Press
2014-05-23 09:14
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-06-13 21:01
Publish the Manuscript Online
2014-06-16 15:44
ISSN 1948-9358 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology and Pharmacy
Manuscript Type Minireviews
Article Title Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data
Manuscript Source Unsolicited Manuscript
All Author List Jagriti Bhatia, Nanda Gamad, Saurabh Bharti and Dharamvir Singh Arya
Funding Agency and Grant Number
Corresponding author Dr. Jagriti Bhatia, Department of Pharmacology, All India Institute of Medical Sciences, Gautam Nagar, New Delhi-110029, India. jagriti2012@gmail.com
Keywords Type 2 diabetes mellitus; Sodium-glucose co-transporter 2; Canagliflozin; Clinical trial; Safety profile
Core Tip This review article focuses upon the current pharmacokinetic, pharmacodynamic and clinical trial data on the newly introduced sodium-glucose co-transporter 2 inhibitor, canagliflozin, for the treatment of type 2 diabetes mellitus. It also discusses briefly about the safety profile and future prospective of canagliflozin.
Publish Date 2014-06-16 15:44
Citation Bhatia J, Gamad N, Bharti S, Arya DS. Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data. World J Diabetes 2014; 5(3): 399-406
Url http://www.wjgnet.com/1948-9358/full/v5/i3/399.htm
DOI http://dx.doi.org/10.4239/wjd.v5.i3.399
Full Article (PDF) WJD-5-399.pdf
Full Article (Word) WJD-5-399.doc
Manuscript File 9134-Review.docx
Answering Reviewers 9134-Answering reviewers.pdf
Copyright License Agreement 9134-Copyright assignment.pdf
Peer-review Report 9134-Peer review(s).pdf
Scientific Editor Work List 9134-Scientific editor work list.doc